Amgen Q4 revenue up 11% to $9.1B; non-GAAP EPS $5.31 (+13%)

AMGEN INC

2024-FY EPS reported $7.56 revenue$33,424,000,000

Q4 product sales up 11% (14% volume growth); FY product sales up 19% (23% volume growth).
GAAP EPS $1.16 vs $1.42; FY $7.56 vs $12.49, driven by mark-to-market losses on equity investments.
Non-GAAP EPS $5.31 vs $4.71; FY $19.84 vs $18.65, driven by higher revenues offset by higher expenses.
Full-year free cash flow $10.4B vs $7.4B in 2023, driven by business performance and working capital timing.
21 products achieved record full-year sales; rare disease sales $1.2B in Q4.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.